Neuronetics Inc. (STIM)
| Bid | 3.55 |
| Market Cap | 251.41M |
| Revenue (ttm) | 74.89M |
| Net Income (ttm) | -43.2M |
| EPS (ttm) | -1.38 |
| PE Ratio (ttm) | -2.77 |
| Forward PE | -4.28 |
| Analyst | Buy |
| Ask | 4.14 |
| Volume | 590,654 |
| Avg. Volume (20D) | 1,552,237 |
| Open | 3.91 |
| Previous Close | 3.79 |
| Day's Range | 3.65 - 3.86 |
| 52-Week Range | 0.52 - 5.92 |
| Beta | 1.98 |
About STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, ...
Analyst Forecast
According to 4 analyst ratings, the average rating for STIM stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 83.25% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Neuronetics: Explosive Growth Poised To Soar On FDA BreakthroughsNeuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite re...
